Treatment-resistant schizophrenia care formalises around clozapine integration
Clozapine pathway formalisation, KarXT muscarinic mechanism integration, and emerging mechanism-targeted programs are reshaping treatment-resistant schizophrenia.
Treatment-resistant schizophrenia (TRS) has been a clozapine category that is structurally underutilised due to monitoring requirements and historic concerns. Clozapine integration pathways are formalising in major health systems, KarXT (xanomeline-trospium, the muscarinic mechanism class) is approved for schizophrenia broadly (September 2024) and is being explored in TRS settings via post-approval research and case reports, and emerging mechanism-targeted programs (GlyT1 inhibitors, novel GABA modulators, others) are in late-stage trials. The infrastructure question (clozapine prescribing capacity, monitoring infrastructure) is the addressable-population enabler.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.